Press release 28-06-2019

Biotype Diagnostic and Biotype Innovation join forces

Dresden-Hellerau, June 28th 2019. We are excited to announce that Biotype Diagnostic GmbH and Biotype Innovation GmbH have decided to merge their capabilities to form one strong entity.

The two biotech companies have been close cooperation partners for the last few years. With effect from 13th June 2019, they officially operate as a single entity under the name Biotype GmbH.

Biotype GmbH unifies the core competences and best practices of both companies to provide innovative diagnostic solutions. By combining existing resources and exploiting synergies we can enhance our product and service offering. The broadened product portfolio comprises molecular diagnostic assays for various application areas and different platforms, such as the innovative Modaplex technology and commercial qPCR devices. We will continue to provide our premium contract development and manufacturing service for third parties like pharma and biotech companies.

In general, there will be no change for our customers and cooperation partners. The certification of Biotype Innovation GmbH will remain valid for Biotype GmbH until the next certification audit. The joint Biotype team, consisting of about 70 employees, will be led by the former CEO’s of Biotype Diagnostic and Biotype Innovation, Dr. Wilhelm Zörgiebel and Dr. Karim Tabiti, respectively. All additional information about the combined company can be found in our imprint.

Do let us know, if you have any queries about the merger. We will be happy to assist you.

Biotype will continue to develop its existing product portfolio to meet the demands of medical professionals from around the world. We look forward to shaping Biotype’s future development in close cooperation with all our clients and partners.